Precigen (NASDAQ:PGEN) Director Nancy Agee Acquires 3,411 Shares

Precigen, Inc. (NASDAQ:PGEN) Director Nancy Agee purchased 3,411 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was bought at an average cost of $7.23 per share, for a total transaction of $24,661.53. Following the completion of the purchase, the director directly owned 309,187 shares in the company, valued at $2,235,422.01. This represents a 1.12% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Precigen Trading Up 1.5%

PGEN stock opened at $7.28 on Wednesday. Precigen, Inc. has a 12-month low of $2.99 and a 12-month high of $7.55. The business’s 50-day moving average is $5.91 and its 200 day moving average is $4.69. The company has a current ratio of 4.58, a quick ratio of 3.89 and a debt-to-equity ratio of 2.15. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -7.00 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. The business had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company’s revenue was up 6322.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Precigen, Inc. will post 0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Precigen

A number of institutional investors have recently added to or reduced their stakes in PGEN. State of Wyoming purchased a new stake in Precigen in the 1st quarter valued at $27,000. NBC Securities Inc. purchased a new position in shares of Precigen during the 4th quarter worth $38,000. Mason Investment Advisory Services Inc. acquired a new position in shares of Precigen during the 4th quarter valued at about $42,000. Abel Hall LLC acquired a new position in shares of Precigen during the 4th quarter valued at about $44,000. Finally, Royal Bank of Canada grew its holdings in shares of Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Wall Street Analyst Weigh In

PGEN has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. HC Wainwright increased their target price on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Citizens Jmp boosted their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Finally, Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong PAPZIMEOS sales and quarterly profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the previous quarter. The company said the performance marked a commercial inflection point and helped it achieve quarterly profitability, supporting the stock’s upward momentum. Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
• Positive Sentiment: Pipeline progress adds to the investment case: PRGN-2009 is advancing in HPV-driven cancers, while management highlighted the broader potential of its AdenoVerse therapeutic platform. The combination of commercial revenue and pipeline development is reinforcing expectations for further growth. Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
• Positive Sentiment: New 1-year high: PGEN reached a new 52-week high, signaling strong recent trading momentum as investors responded to the company’s improved operating performance. Precigen Reaches New 1-Year High
• Positive Sentiment: Director purchase: Director Nancy H. Agee bought 3,411 shares at an average price of $7.23, modestly increasing her ownership. The purchase may be viewed as a sign of confidence in Precigen’s outlook.
• Neutral Sentiment: COO share sales were tax-related: COO Rutul R. Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the sales were planned and administrative, they provide limited bearish information, although they reduce his holdings.
• Neutral Sentiment: Short-interest data is inconclusive: Reported short interest was zero, making the published change and short-interest ratio unreliable as indicators of investor positioning.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.